437 related articles for article (PubMed ID: 30700545)
1. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.
Chen IX; Chauhan VP; Posada J; Ng MR; Wu MW; Adstamongkonkul P; Huang P; Lindeman N; Langer R; Jain RK
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4558-4566. PubMed ID: 30700545
[TBL] [Abstract][Full Text] [Related]
2. Targeting CXCL12-CXCR4 Signaling Enhances Immune Checkpoint Blockade Therapy Against Triple Negative Breast Cancer.
Lu G; Qiu Y; Su X
Eur J Pharm Sci; 2021 Feb; 157():105606. PubMed ID: 33131745
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis.
Martinez-Ordoñez A; Seoane S; Cabezas P; Eiro N; Sendon-Lago J; Macia M; Garcia-Caballero T; Gonzalez LO; Sanchez L; Vizoso F; Perez-Fernandez R
Oncogene; 2018 Mar; 37(11):1430-1444. PubMed ID: 29321662
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell.
Wang Z; Sun J; Feng Y; Tian X; Wang B; Zhou Y
Tumour Biol; 2016 Jul; 37(7):8515-28. PubMed ID: 27079871
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response.
Biasci D; Smoragiewicz M; Connell CM; Wang Z; Gao Y; Thaventhiran JED; Basu B; Magiera L; Johnson TI; Bax L; Gopinathan A; Isherwood C; Gallagher FA; Pawula M; Hudecova I; Gale D; Rosenfeld N; Barmpounakis P; Popa EC; Brais R; Godfrey E; Mir F; Richards FM; Fearon DT; Janowitz T; Jodrell DI
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28960-28970. PubMed ID: 33127761
[TBL] [Abstract][Full Text] [Related]
6. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Zhou W; Guo S; Liu M; Burow ME; Wang G
Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
[TBL] [Abstract][Full Text] [Related]
7. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
[TBL] [Abstract][Full Text] [Related]
8. ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer.
Wang G; Romero Y; Thevarajan I; Zolkiewska A
Oncoimmunology; 2023; 12(1):2158006. PubMed ID: 36545255
[TBL] [Abstract][Full Text] [Related]
9. CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells.
Dürr C; Pfeifer D; Claus R; Schmitt-Graeff A; Gerlach UV; Graeser R; Krüger S; Gerbitz A; Negrin RS; Finke J; Zeiser R
Cancer Res; 2010 Dec; 70(24):10170-81. PubMed ID: 21159639
[TBL] [Abstract][Full Text] [Related]
10. Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis.
Wu R; Yu W; Yao C; Liang Z; Yoon Y; Xie Y; Shim H; Bai R
Eur J Med Chem; 2020 Jan; 185():111823. PubMed ID: 31698158
[TBL] [Abstract][Full Text] [Related]
11. The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo.
Ling X; Spaeth E; Chen Y; Shi Y; Zhang W; Schober W; Hail N; Konopleva M; Andreeff M
PLoS One; 2013; 8(3):e58426. PubMed ID: 23484027
[TBL] [Abstract][Full Text] [Related]
12. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.
Katkoori VR; Basson MD; Bond VC; Manne U; Bumpers HL
Oncotarget; 2015 Sep; 6(29):27763-77. PubMed ID: 26318034
[TBL] [Abstract][Full Text] [Related]
13. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?
Hirbe AC; Morgan EA; Weilbaecher KN
Curr Pharm Des; 2010; 16(11):1284-90. PubMed ID: 20166978
[TBL] [Abstract][Full Text] [Related]
14. CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice.
Brennecke P; Arlt MJ; Campanile C; Husmann K; Gvozdenovic A; Apuzzo T; Thelen M; Born W; Fuchs B
Clin Exp Metastasis; 2014 Mar; 31(3):339-49. PubMed ID: 24390633
[TBL] [Abstract][Full Text] [Related]
15. Functions of CXCL12 and CXCR4 in breast cancer.
Luker KE; Luker GD
Cancer Lett; 2006 Jul; 238(1):30-41. PubMed ID: 16046252
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
Yang F; Takagaki Y; Yoshitomi Y; Ikeda T; Li J; Kitada M; Kumagai A; Kawakita E; Shi S; Kanasaki K; Koya D
Cancer Res; 2019 Feb; 79(4):735-746. PubMed ID: 30584072
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic knockout of CXCR4 by a novel recombinant protein TAT/54R/KDEL inhibits tumors metastasis.
Ma WF; Du J; Fu LP; Fang R; Chen HY; Cai SH
Mol Cancer Res; 2009 Oct; 7(10):1613-21. PubMed ID: 19825996
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids?
Harvey JR; Mellor P; Eldaly H; Lennard TW; Kirby JA; Ali S
Clin Cancer Res; 2007 Mar; 13(5):1562-70. PubMed ID: 17332302
[TBL] [Abstract][Full Text] [Related]
19. Krüppel-like factor 8 activates the transcription of C-X-C cytokine receptor type 4 to promote breast cancer cell invasion, transendothelial migration and metastasis.
Mukherjee D; Lu H; Yu L; He C; Lahiri SK; Li T; Zhao J
Oncotarget; 2016 Apr; 7(17):23552-68. PubMed ID: 26993780
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer metastasis: demonstration that FOXP3 regulates CXCR4 expression and the response to CXCL12.
Douglass S; Meeson AP; Overbeck-Zubrzycka D; Brain JG; Bennett MR; Lamb CA; Lennard TW; Browell D; Ali S; Kirby JA
J Pathol; 2014 Sep; 234(1):74-85. PubMed ID: 24870556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
